Stock Events

Stock Events

Nuvectis Pharma 

$8.42
13
+$0.06+0.72% Today

Statistics

Day High
8.6
Day Low
8.37
52W High
11.52
52W Low
5.55
Volume
1,596
Avg. Volume
84,670
Mkt Cap
215.68M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10MarExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Next
-0.44
-0.37
-0.31
-0.24
Expected EPS
-0.308
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
0Revenue
-38MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NVCT. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. is a global healthcare company that develops medications in oncology, making it a direct competitor in the cancer treatment market where Nuvectis Pharma operates.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb is involved in the discovery, development, and delivery of cancer therapies, competing directly with Nuvectis Pharma in the oncology sector.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. has a broad portfolio of oncology drugs and invests heavily in cancer research, positioning it as a competitor to Nuvectis Pharma in the development of cancer treatments.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca PLC focuses on the development of new cancer drugs, including targeted therapies, competing with Nuvectis Pharma in the oncology pharmaceuticals market.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, Inc. is known for its innovative therapies in oncology, directly competing with Nuvectis Pharma in the cancer treatment space.
AMGEN
AMGN
Mkt Cap160.66B
Amgen Inc. has a strong presence in the oncology market with a focus on developing novel cancer treatments, making it a competitor to Nuvectis Pharma.
Rogers
ROG
Mkt Cap1.57B
Roche Holding AG is a major player in oncology, with a wide range of cancer drugs and therapies that compete with Nuvectis Pharma's offerings.
Novartis
NVS
Mkt Cap237.61B
Novartis AG is heavily involved in oncology research and drug development, offering a broad portfolio of cancer treatments that compete with Nuvectis Pharma.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, Inc. is engaged in the development of cancer treatments, including immunotherapies, which positions it as a competitor to Nuvectis Pharma.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly and Company has a growing oncology division focused on developing innovative cancer treatments, competing with Nuvectis Pharma in the pharmaceuticals market.

About

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
Show more...
CEO
Mr. Ron Bentsur M.B.A.
Employees
13
Country
US
ISIN
US67080T1088

Listings

BOATS
BOATS
NVCT.BOATS
XNAS
US
NVCT

0 Comments

Share your thoughts

FAQ

What is Nuvectis Pharma stock price today?▼
The current price of NVCT is $8.42 USD — it has increased by +0.72% in the past 24 hours. Watch Nuvectis Pharma stock price performance more closely on the chart.
What is Nuvectis Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Nuvectis Pharma stocks are traded under the ticker NVCT.
Is Nuvectis Pharma stock price growing?▼
NVCT stock has fallen by -5.49% compared to the previous week, the month change is a -2.82% fall, over the last year Nuvectis Pharma has showed a +21.62% increase.
What is Nuvectis Pharma market cap?▼
Today Nuvectis Pharma has the market capitalization of 215.68M
When is the next Nuvectis Pharma earnings date?▼
Nuvectis Pharma is going to release the next earnings report on March 10, 2026.
What were Nuvectis Pharma earnings last quarter?▼
NVCT earnings for the last quarter are -0.44 USD per share, whereas the estimation was -0.25 USD resulting in a -76% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Nuvectis Pharma revenue for the last year?▼
Nuvectis Pharma revenue for the last year amounts to 0 USD.
What is Nuvectis Pharma net income for the last year?▼
NVCT net income for the last year is -38M USD.
How many employees does Nuvectis Pharma have?▼
As of February 03, 2026, the company has 13 employees.
In which sector is Nuvectis Pharma located?▼
Nuvectis Pharma operates in the Health Care sector.
When did Nuvectis Pharma complete a stock split?▼
Nuvectis Pharma has not had any recent stock splits.
Where is Nuvectis Pharma headquartered?▼
Nuvectis Pharma is headquartered in Fort Lee, US.